Premium
MDR1 polymorphism influences the outcome of multiple myeloma patients
Author(s) -
Buda Gabriele,
Maggini Valentina,
Galimberti Sara,
Martino Alessandro,
Giuliani Nicola,
Morabito Fortunato,
Genestreti Giovenzio,
Iacopino Pasquale,
Rizzoli Vittorio,
Barale Roberto,
Rossi Anna M.,
Petrini Mario
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06605.x
Subject(s) - multiple myeloma , medicine , outcome (game theory) , oncology , polymorphism (computer science) , genetics , biology , genotype , gene , mathematics , mathematical economics
The multidrug resistance gene ( MDR1 ) has been reported to be an additional prognostic factor in acute myeloid leukaemia patients. This study evaluated the prognostic role of MDR1 in the outcome of 115 multiple myeloma patients treated with DAV (dexamethasone, doxorubicin [adryamicin] and vincristine) regimen followed by autologous transplantation. In particular, when investigating the C3435T polymorphism, a prognostic value of MDR1 genotypes for overall survival (OS) was observed. Our data suggested a longer OS for patients with C/T and T/T genotypes (log‐rank test, P = 0·02) compared with patients with C/C genotype.